
Eli Lilly beats Q2 earnings and revenue estimates, raises full-year outlook on soaring Zepbound and Mounjaro demand
Eli Lilly reported Q2 earnings and revenue that beat estimates, driven by surging demand for weight loss drug Zepbound and diabetes treatment Mounjaro, while raising its full-year sales outlook.

















